rayiot- non-contact health monitoring

During the current pandemic outbreak, we stay focused on saving lives with predictive analysis and technology that can provide clinical grade health monitoring accessible to a larger population in need. We have developed a non-contact technology for health monitoring that can be integrated with existing consumer wifi devices. Our versatile platform enables easy adaptation of technology, least intrusively without investing in a medical equipment or technical supervision to operate. rayiot technology can also deployed for remotely monitoring multiple patients at a time, from the comfort of the users' own devices and environments. With our rental model, COVID patients can also use the technology for the prescribed quarantine duration. With the power of AI, caregivers can now provide resources to the right patients without the risk of spreading the infection.

In the COVID-19 pandemic scenario, no country has been equipped with resources to handle the outbreak sufficiently. We are leveraging predictive analysis to bring down mortality from preventable causes. Our non-contact AI powered solution can help manage the available resources intelligently through all phases of the outbreak as follows:-

Home quarantined population: 80% of infected are asymptomatic, who can be monitored for deterioration at an early stage and remotely without increasing the hospital influx and thereby cases of hospital acquired infection.

Isolation or Quarantine Centres: Track recovery through the infection by ensuring your breathing rate is stable.

Doctors in Critical Care: Without getting exposed to the infection repeatedly, our central database along with video and audio facilities can helps in categorizing cases based on criticality, monitor and direct resources to the right patients.

Researchers and Pharma Companies: Help in testing the extent of drug or vaccine effectiveness. 

Government bodies: Our database that categorizes patients into mild, severe and critical can help authorities to strategize redistribution of resources to make it accessible to the critical cases efficiently.

IoT based Hardware Companies: Our versatile AI platform enables our algorithms to be integrated with existing IoT hardware.

rayiot is a non-contact health monitoring platform that can be integrated with existing consumer wifi devices from wearables and phones to card and refrigerators. It uses low power radio waves along with digital signal processing algorithms to capture vitals, predominantly breathing rate along with sleep and movement. It uses AI for predictive analysis of possible health conditions. The AI powered platform draws trends of their vitals to predict occurrence of any episode of sleep apnea, fever or asthma to name a few. It updates breathing rate values in the shortest intervals of 5 seconds and does not require any clinical supervision. The device is completely automated and can be controlled with a remote application as well. 

Our range of products serve multiple segments of the market-infants to elderly and government bodies to MNCs with both B2B and B2C models.Our primary customers for the B2B products are hospitals, consumer electronics companies and even automobile companies looking to deliver better safety to their end users by monitoring their vitals so as to save lives. Pertaining to the COVID-19 scenario, we have worked closely with Hospitals in India to evaluate the performance in an ICU setting. rayiot technology has also been tested for reliability in quarantine environments and has achieved 98% accuracy in both cases. Two verticals of the technology has been developed based on studying market and directly from among 3000 customers. User behavior is studied closely and periodic feedback surveys are conducted as well. Clinical experts are also consulted for validation. Features of interest are incorporated with an eye for customization of technology. We have evolved our products to a stage where we have strategized in making clinical grade health monitoring accessible to a larger population without heavy investment in medical equipment or technical supervision to use the technology. Our technology saves both the patients and caregivers from the risks of infection arising from multiple exposures.

Early in the outbreak itself, the threat of being under equipped to handle the pandemic became a global threat. The lack of doctors, hospital beds and medical equipment along with the healthcare expense in a dipping economy could only show potential for intelligently managing the available resources. Our non contact technology helps both the caregivers and affected population to be connected without the risk of infection. rayiot can be integrated with the existing consumer wifi hardwares and can also be rented for the subscribed quarantine period without investing in medical equipment.It can also be deployed to monitor multiple patients simultaneously.

Our top three competitors would be Apple Watch, Fit Bit and Nanit. Our non-contact technology makes us unique. Further, our data analysis is through sensors unlike the majority players that use computer vision. This makes us more accurate. With our continuous testing and evaluation of our AI powered platform, we are able to predict the occurrence of an episode than merely detect it. The COVID-19  outbreak has just made early detection and access to health monitoring more essential.Further a medical equipment that monitors your vitals easily runs into lacs and requires technical expertise to operate. We have honed our products to be in par with medical grade devices when it comes to credibility of our algorithms. The following features, combined make us a unique fit.

• Completely non-contact 

• Monitors breathing, movement and sleep

• Does not require patient to be stationary

• Remote monitoring with tele-consultation facility

• Continuous & real-time monitoring of upto 5 lakhs patients at a time

• Clinical grade algorithms integratable with existing IoT hardwares

• Comprehensive and connected cloud based workflow with integrated SOS system

• Customizable business models 

• Single device for early indication of 30+ health conditions including pneumonia, alzheimers and heart attacks through breathing trends

• Proven 98% accuracy w.r.t clinical and industry standard 

• Over 500 hours of evaluation in ICU and home settings

• No technical supervision required for operation

• Portable plug and play technology with minimal training

With the research at rayIOT Solutions Inc, we introduce radiosomnography, a method of monitoring health and wellness data using low-power radio waves. Our flagship product, raybaby®, is the world’s first non-contact radar-based health and sleep monitoring system for infants. Since its launch, we have ramped up to a full fledged AI powered platform that can perform predictive analysis on data captured through low power radio waves and digital sognal processing. Our software platform is designed to be versatile and hence can be integrated with existing consumer wifi devices. The flexible business models enable easier adaptation through both B2B and B2C models. Our product can work with our without the rayiot hardware and is largely customizable to be adaptable from devices like phones and wearables to cars and refrigerators.

At rayIoT, we have a dedicated wing for clinical research and continue to identify multiple use cases to establish credibility to our technology. There are multiple paper undergoing review for publication in medical and engineering portals. The technology has undergone multiple rounds of rigorous testing and close to 800 hours of evaluation with respect to medical and industry standards for clinical and non-clinical settings. It has achieved 98% accuracy in both scenarios. A huge no.of reference papers and validation works are being updated on this link periodically: https://drive.google.com/drive/u/0/folders/1CX9ATUx122PZKFGoxBnK0jw10QN87AVf

rayIoT has till date achieved ethical clearance for 2 clinical studies w.r.t FDA approved devices and multiple phases of studies to understand reliability in non-clinical settings as well. Over 7 Billion breathing instances capturing variations during fever, asthma and sleep apnea with 98% accuracy has been covered by the technology. rayIoT also has to its merit, a patented technology and over 3000 units sold since online launch in 2018. It is backed by top hospitals and doctors in the country. Our technology is FCC approved and FSA Compliantand available in top stores including Target and Amazon in US, Media coverage by WIRED, CNN & more

Since its inception, RayIoT has been privileged to be featured in the likes of Wired and CNBC to TechCrunch, along with other awards and accolades. As a company, we have hit 300 percent YoY growth from 2018 when we launched our other products. We have attained an ARR of $750,000 in less than a year of launching the product and acquired more than 3,000 customers in the past 12 months. At a peak of 1,00,000 new cases in India, our devices can cover 12500 cases for 14 days considering even distribution with our available capacity of 5000 readily deployable devices. With 10K units, we can directly cover 50% of the infected population over the 2 month peak period. Through this period, we plan to increase our manufacturing capacity by 10x to produce 100K units/month.  

Our vision is to empower even the early IoT devices with clinical grade technology for health monitoring. We envision saving lives with the power of predictive analysis by our novel technology powered by AI. We aim to achieve an ARR of $ 20 Million from a 10% penetration in the US mobile phone market. Although we have established our presence in the US market, we look at evolving our product ranges to provide access to quality health monitoring in SouthEast Asia and African countries. We believe in equal rights to quality health monitoring for all and we work towards building user-friendly technology that can be easily adapted. We also aim to build a repository from billions of data we have collected with our tech so that it can be utilised for research and predictive analysis as well as a tool for the extent of effectiveness of a drug or treatment. With a pool of interdisciplinary talent, we plan to build products that can be customised to an extent that prevention and early detection becomes the norm and help people live a better lifestyle. We look at collaborating and serving multiple segments of the population, from infants to seniors, and government bodies to big pharmaceutical MNCs to use the power of vitals monitoring early on and cost-effectively.

We currently have a customer base of 3000. We are actively collaborating with Hospitals for multiple clinical studies that will run into hundreds of patients. With our rental model, we look at reaching out to people in exponential numbers through the current scenario.

We aim to achieve an ARR of $ 20 Million from a 10% penetration in the US mobile phone market. Although we have established our presence in the US market, we look at evolving our product ranges to provide access to quality health monitoring in SouthEast Asia and African countries.

We aim to enable integration of rayiot’s technology with the existing IoT hardwares and mobile devices, thereby making health monitoring accessible to a larger population. 

We plan to customise our algorithms platform as a part of existing consumer devices, reducing the effort to familiarise while adopting a new technology.
Alternatively, for every patient detected with COVID-19, we plan to rent our technology to monitor their health for the 14 days of the prescribed quarantine. This way, without investing on a device, patients will have their health monitored by doctors from anywhere in a cost effective manner.
At a peak of 1,00,000 new cases in India, our devices can cover 12500 cases for 14 days considering even distribution with our available capacity of 5000 readily deployable devices. With 10K units, we can directly cover 50% of the infected population over the 2 month peak period. 
With our flexible business models, we look towards enabling people access to clinical grade accuracy without having to invest in medical equipment. 
Through this period, we plan to increase our manufacturing capacity by 10x to produce 100K units in a month. We also work towards getting our technology , which already has 800+ hours of clinical evaluation with 98% accuracy, to be evaluated w.r.t multiple clinical and industrial standards. 
We are also hoping to scale up to deliver to South East Asia, Middle East & African countries, with regulatory compliance required for each market we serve.

Following are the barriers we anticipate in the future in our journey in making healthcare less intrusive and exploring the clinical potential of our technology:-

Manufacturing setup to ramp-up at global scale.

Funds for logistics and remunerations

Costs involved in country specific regulatory compliance requirements

Costs involved to copyright and patent indigenous technology

We are looking are collaborating with known players in various fields to expand our market presence. We focus on improving our technology's credibility through indepth research and clinical validation. We also aim at studying the market thoroughly and strategising to innovate in business processes as well to be suitable for developing countries as well.We plan to tweak our offerings time to time and acquire timely funding for the same.

We have also identified the following plans to expand our reach:-

B2C: We are in the process of acquiring users so device sales are our only source of revenue right now which currently added USD 750,000 to our revenues. We have been able to acquire over 3000 users in just a years’ time.We are also planning to add subscription and tiering for our software. Launching of a rental/Subscription model for our hardware will be reducing the barrier for adopters as well. This is estimated to  potentially add $1 Million ARR to us once the lock down is eased.

B2B: We are exploring various Business models on this front, as listed below:-

Revenue sharing on each device sold with rayIot tech in it

Bulk pricing for the solution

For hospitals, we are exploring a per device cost combined with software subscription pricing and maintenance costs. 

As our Business lines are evolving and we add more products to our offerings, we are looking at the flexible business model that best suits our users and maximising value addition.

We have a team of 22 Full time members working on the solution- split into teams of R&D, Engineering, Clinical Research, Operations, Finance, Marketing and Sales. We have consultants when it comes to legal and other need based requirements.

rayIoT Solutions Inc is a young team of interdisciplinary innovators, predominantly engineers from different streams with a track record of solving the toughest problems. We have a team of researchers and subject experts from Medical Engineering to Artificial Intelligence and, Industrial Design & Manufacturing to Marketing & Sales. Our team involves multiple patent holders and published scientific authors to disruptive innovators in creative marketing. We have gathered talent that has a proven track record of collaborative projects with multiple disciplines of technology and marketing. 

Ranjana Nair, Co-founder & CEO, is listed her as one of the "Top 3 female leaders of the emerging IoT product companies in Asia" by Tech Influencer Sandy Carter and IoT Institute's Brian Buntz. Along with Ranjana, co-founders Aardra Kannan Ambili and Sanchi Poovaya form the founding team of RayIoT, which makes it the #3 among the Top 25 female founded IoT startups in the world. Aardra Kannan Ambili, Co-founder & CTO, has been building products that solve varied problems - wearable devices for women's safety, a device to monitor an epilepsy patient’s attacks, and even algorithms that were used by political psychologists. Sanchi Poovaya, Co-founder & COO, is a mechanical engineer with over 12 years of experience that includes a hands on involvement in business development as well. The trio comes with a cumulative experience of over 30 years in industry and research, developing cutting edge AI-powered healthcare systems.

Our range of products serve multiple segments of the market-from infants to elderly and government bodies to pharma MNCs.

Our primary customers for the B2B products are identified to be hospitals, consumer electronics companies and even automobile companies looking to deliver better safety to their end users by monitoring their vitals so as to save lives.

Our revenue model / business model is described below:
B2C: We sell through retailers like AZ and FSA. They share a cut of the price markup. We are in the process of acquiring users so device sales are our only source of revenue right now which currently added USD 750,000 to our revenues. We have been able to acquire over 3000 users in just a years’ time.We are also planning to add subscription and tiering for our software. Launching of a rental/Subscription model for our hardware will be reducing the barrier for adopters as well. This is estimated to  potentially add $1 Million ARR to us once the lock down is eased.
B2B: We are exploring various Business models on this front, as listed below:-
Revenue sharing on each device sold with rayIot tech in it
Bulk pricing for the solution
For hospitals, we are exploring a per device cost combined with software subscription pricing and maintenance costs. 
As our Business lines are evolving and we add more products to our offerings, we are looking at the flexible business model that best suits our users and maximising value addition.

Combination of grants, sales and further rounds of raising investment capital. Collaboration and royalty from patents and publications.